Business
Journey Medical Corporation Announces Publication of Clinical Trial Results Assessing the Impact of Emrosi™ (DFD-29) on Microbial Flora of Healthy Adults in the Journal of Drugs in Dermatology
Clinical trial achieved all three primary objectives with no significant safety issues being reported Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults SCOTTSDALE, Ariz., Dec. 10, 2025 (GL
About this update from Journey Medical Corporation
[{"type":"image","alt":"Journey Medical Corporation","displaySize":"","headline":null,"caption":"Journey Medical Corporation","className":"","disableSlideshowImg":false,"size":{"original":{"width":210,"height":91,"url":"https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/hjjUQ.iXZdhdLwOzj17HjA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE4MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/e9d5afac46b9f27fa4ee4033197e08d3","width":210,"height":91}},"lazy":false},{"type":"text","content":"Clinical trial achieved all three primary objectives with no significant safety issues being reported","length":101,"tagName":"p"},{"type":"text","content":"Results indicate that Emrosi can be safely used for up to 16 weeks with no detectable impact on skin, GI tract or vaginal microbiota","length":132,"tagName":"p"},{"type":"text","content":"FDA-approved Emrosi (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) is available in the United States for the treatment of inflammatory lesions of rosacea in adults","length":228,"tagName":"p"},{"type":"text","content":"SCOTTSDALE, Ariz., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that results from the Phase 1 clinical trial (DFD-29-CD-006) assessing the impact of low-dose oral minocycline (“DFD-29” or commercially known as “Emrosi™) on skin, gastrointestinal (“GI”) and vaginal microflora in healthy adults were published in the Journal of Drugs in Dermatology, a leading peer-reviewed publication in clinical dermatology. The clinical trial also assessed the safety and tolerability of the treatment. The results indicate that DFD-29 administration for 16 weeks had no detectable effects on skin, GI tract or vaginal microflora and it was well tolerated in healthy adults, supporting its use as a therapeutic option for patients with moderate-to-severe rosacea.","length":1039,"tagName":"p"},{"type":"text","content":"“We are very pleased to see these important data published in the Journal of Drugs in Dermatology,” s...